RECBIO-B(02179),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02179 RECBIO-B

Market Closed 02-27 09:57:12

4.500

+0.000

0.00%

High4.500	Low4.500	Vol500.00
Open4.500	D1 Closing4.500	Amplitude0.00%
Mkt Cap2.82B	Tradable Cap1.42B	Total Shares626.00M
T/O2.25K	T/O Rate0.00%	Tradable Shares316.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02179","market":"HK","secType":"STK","nameCN":"RECBIO-B","latestPrice":4.5,"timestamp":1772157432465,"preClose":4.5,"halted":0,"volume":500,"delay":0,"changeRate":0,"floatShares":316000000,"shares":626000000,"eps":-1.164922,"marketStatus":"Market Closed","change":0,"latestTime":"02-27 09:57:12","open":4.5,"high":4.5,"low":4.5,"amount":2250,"amplitude":0,"askPrice":4.69,"askSize":500,"bidPrice":4.5,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-1.145,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":7,"adr":0,"listingDate":1648656000000,"exchange":"SEHK","adjPreClose":4.5,"openAndCloseTimeList":[[1772155800000,1772164800000],[1772168400000,1772179200000]],"volumeRatio":0.06239393125277924,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02179","defaultTab":"news","newsList":[{"id":"2610688925","title":"Jiangsu Recbio Gets HKEX Approval for Hong Kong Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610688925","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610688925?lang=en_us&edition=fundamental","pubTime":"2026-02-09 12:31","pubTimestamp":1770611471,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology  said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Feb. 6 bourse filing.The approval covers the conversion of about 142 million unlisted shares into Hong Kong-listed shares.The converted shares represent about 22.67% of the company's total issued share capital.Upon completion of the conversion, Jiangsu Recbio's H-shares will increase to about 458.1 million, accounting for roughly 73.17% of total issued shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0594300419.USD","HKXCY","LU1993786604.SGD","LU0067412154.USD","LU2226246903.HKD","00388","LU0261947096.USD","LU0572944931.SGD","IE00B3T34201.USD","LU0819123356.HKD","LU1282648689.USD","02179","LU0540923850.HKD","LU0886674414.USD","LU0456846285.SGD","LU0791590937.USD","LU0417516738.SGD","LU0359202008.SGD","LU0955648018.USD","IE00BKZH1Z71.USD","SG9999004220.SGD","LU1813983027.USD","LU1282649810.SGD","LU0762541174.USD","LU0955623706.USD","LU0488056044.USD","LU0314109678.HKD","LU1044876610.USD","LU0831093199.SGD","SG9999002562.SGD","LU0561508036.HKD","LU0320764599.SGD","LU0762542818.HKD","80388","LU1366334651.USD","LU1226287529.USD","LU0797268264.HKD","LU0072462343.USD","LU0856984785.SGD","SG9999002463.SGD","LU1242518857.USD","LU0359201612.USD","LU0648948544.HKD","LU0197773673.USD","LU0501845795.SGD","LU1044875133.USD","LU1211504680.USD","IE0003795394.USD","LU2039709279.SGD","HEXmain"],"gpt_icon":0},{"id":"1135343398","title":"Jiangsu Recbio (2179) Announces H Share Full Circulation Listing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1135343398","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135343398?lang=en_us&edition=fundamental","pubTime":"2026-02-06 19:42","pubTimestamp":1770378146,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co., Ltd. (stock code: 2179) announced that it received listing approval from The Stock Exchange of Hong Kong Limited on February 5, 2026 for converting 141,953,489 unlisted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"gpt_icon":0},{"id":"1198911641","title":"RECBIO-B Granted Listing Approval by Stock Exchange for H Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1198911641","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198911641?lang=en_us&edition=fundamental","pubTime":"2026-02-06 19:38","pubTimestamp":1770377907,"startTime":"0","endTime":"0","summary":"RECBIO-B (02179) has announced that the company received approval from the Stock Exchange on February 5, 2026, for the listing and trading of 142 million H shares.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179","BK1161"],"gpt_icon":0},{"id":"1108684931","title":"Jiangsu Recbio Technology (02179) Announces January 2026 Monthly Return on Movements in Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1108684931","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108684931?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:04","pubTimestamp":1770023084,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co., Ltd. (02179) reported that, as of January 31, 2026, the total authorized share capital remained at RMB 626,075,702. This comprises 297,937,013 Domestic Shares,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"gpt_icon":0},{"id":"1176846253","title":"RECBIO-B Receives CSRC Filing Notice for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1176846253","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176846253?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:04","pubTimestamp":1769994241,"startTime":"0","endTime":"0","summary":"RECBIO-B (02179) announced that the company has recently received a filing notice from the China Securities Regulatory Commission (CSRC) dated January 13, 2026, regarding its H-share full circulation...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0},{"id":"1163956745","title":"RECBIO-B (02179): China Securities Regulatory Commission Issues Filing Notice for Company's H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1163956745","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163956745?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:48","pubTimestamp":1769784495,"startTime":"0","endTime":"0","summary":"RECBIO-B (02179) announced that the company has recently received a filing notice from the China Securities Regulatory Commission (CSRC) dated January 13, 2026, regarding its H-share full circulation...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0},{"id":"1152580502","title":"Jiangsu Recbio Technology (2179) Receives CSRC Filing Notice for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1152580502","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152580502?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:45","pubTimestamp":1769784327,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co., Ltd. (Stock Code: 2179) announced that it has obtained a filing notice dated January 13, 2026 from the China Securities Regulatory Commission (CSRC), confirming...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"gpt_icon":0},{"id":"2607804195","title":"Jiangsu Recbio Receives CSRC Filing Notice for H Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804195","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607804195?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:39","pubTimestamp":1769783990,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co. Ltd. announced that it has received a filing notice dated January 13, 2026, from the China Securities Regulatory Commission  regarding its H Share Full Circulation Plan. The company indicated that the details of the implementation plan, including the conversion and listing of shares, have not yet been finalized and remain subject to additional procedures required by the Stock Exchange of Hong Kong and other regulatory authorities. Jiangsu Recbio stated it will provide further updates as the process progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Recbio Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL2SvrfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0},{"id":"2602593074","title":"Haoyu Xu Spends CN¥1.7m Buying Jiangsu Recbio Technology Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602593074","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602593074?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:28","pubTimestamp":1768177719,"startTime":"0","endTime":"0","summary":"Potential Jiangsu Recbio Technology Co., Ltd. ( HKG:2179 ) shareholders may wish to note that insider Haoyu Xu recently...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2179/jiangsu-recbio-technology-shares/news/haoyu-xu-spends-cn17m-buying-jiangsu-recbio-technology-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2179/jiangsu-recbio-technology-shares/news/haoyu-xu-spends-cn17m-buying-jiangsu-recbio-technology-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02179","CN"],"gpt_icon":0},{"id":"1121800957","title":"RECBIO-B (02179): New Drug Application for Novel Adjuvant Recombinant Shingles Vaccine REC610 Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1121800957","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121800957?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:54","pubTimestamp":1767020062,"startTime":"0","endTime":"0","summary":"RECBIO-B (02179) announced that the new drug application for its novel adjuvant recombinant shingles vaccine REC610 has been formally accepted by the Center for Drug Evaluation of the National...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179","159646"],"gpt_icon":0},{"id":"2595736653","title":"China Accepts New Drug Application for Recbio's Recombinant Shingles Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2595736653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595736653?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:45","pubTimestamp":1767019513,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co. Ltd. announced that its new drug application for the novel adjuvanted recombinant shingles vaccine, REC610, has been officially accepted for review by the Center for Drug Evaluation of the National Medical Products Administration. The vaccine, which has demonstrated a favorable safety profile and strong immune response in clinical trials, will now undergo regulatory review in China. No grant or funding beneficiaries other than Jiangsu Recbio Technology Co. Ltd. were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Recbio Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL9Lcllq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0},{"id":"2595689736","title":"Jiangsu Recbio Technology - Application Accepted by Center for Drug Evaluation, Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2595689736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595689736?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:44","pubTimestamp":1767019496,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XY07N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02179"],"gpt_icon":0},{"id":"1149295708","title":"Yangtze River Pharma Boosts Innovative Drug Strategy with Xu Haoyu Appointed as Chairman of Recbio","url":"https://stock-news.laohu8.com/highlight/detail?id=1149295708","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149295708?lang=en_us&edition=fundamental","pubTime":"2025-12-25 10:51","pubTimestamp":1766631071,"startTime":"0","endTime":"0","summary":"On December 23, Recbio (HKEX: 02179) announced that its founder Liu Yong resigned as chairman, citing reasons to \"enhance corporate governance\" and \"devote more time to other commitments.\" Despite...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","02179","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2593211974","title":"Insiders' CN¥12.4m Investments In Red Following Jiangsu Recbio Technology's HK$341m Dip In Market Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2593211974","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593211974?lang=en_us&edition=fundamental","pubTime":"2025-12-24 08:51","pubTimestamp":1766537507,"startTime":"0","endTime":"0","summary":"Insiders who acquired CN¥12.4m worth of Jiangsu Recbio Technology Co., Ltd.'s ( HKG:2179 ) stock at an average price of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2179/jiangsu-recbio-technology-shares/news/insiders-cn124m-investments-in-red-following-jiangsu-recbio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2179/jiangsu-recbio-technology-shares/news/insiders-cn124m-investments-in-red-following-jiangsu-recbio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","CN","02179"],"gpt_icon":0},{"id":"2593416147","title":"BRIEF-Jiangsu Recbio Technology Says Liu Yong Resigned As Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2593416147","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593416147?lang=en_us&edition=fundamental","pubTime":"2025-12-23 22:53","pubTimestamp":1766501616,"startTime":"0","endTime":"0","summary":"BRIEF-Jiangsu Recbio Technology Says Liu Yong Resigned As ChairDec 23 (Reuters) - Jiangsu Recbio Technology 2179.HK:LIU YONG RESIGNED AS CHAIRMANFurther company coverage: 2179.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT09B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179","BK1161"],"gpt_icon":0},{"id":"2593441868","title":"Recbio Technology's Chair Steps Down; Successor Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2593441868","media":"MT Newswires Live","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593441868?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:19","pubTimestamp":1766495970,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology's  Chairman Liu Yong resigned to dedicate more time to other commitments, a Tuesday Hong Kong bourse filing said.Liu will continue to serve as the vaccine maker's general manager.The firm, on Tuesday, named Xu Haoyu as its new chairman.Xu has been the chairman and president of Yangtze River Pharmaceutical  since July 2021.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02179"],"gpt_icon":0},{"id":"1100518873","title":"RECBIO-B (02179): Xu Haoyu Elected as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=1100518873","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100518873?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:50","pubTimestamp":1766490619,"startTime":"0","endTime":"0","summary":"RECBIO-B (02179) announced that the company's board of directors received the resignation letter from Dr. Liu Yong on December 22, 2025. To further enhance corporate governance and allocate more time...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0},{"id":"2593492535","title":"Jiangsu Recbio Files Director List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492535","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593492535?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:47","pubTimestamp":1766490423,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co. Ltd. has filed an updated list of directors and their respective roles with the Hong Kong Stock Exchange. Mr. Xu Haoyu serves as Chairman of the Board and Non-executive Director. The Executive Directors are Dr. Liu Yong, Mr. Wei Qifang, and Ms. Wang Jing. Non-executive Directors include Dr. Wang Ruwei, Dr. Zhang Jiaxin, Dr. Zhou Hongbin, and Mr. Hu Houwei. The Independent Non-executive Directors are Dr. Xia Lijun, Mr. Liang Guodong, Professor Gao Feng, and Professor Yuen Ming Fai. Committee memberships are as follows: Dr. Xia Lijun chairs the Audit Committee, with Professor Yuen Ming Fai as a member. Professor Yuen Ming Fai chairs the Remuneration and Appraisal Committee, joined by Dr. Xia Lijun, Mr. Liang Guodong, and Professor Gao Feng. Professor Gao Feng chairs the Nomination Committee, with Dr. Xia Lijun, Mr. Liang Guodong, and Ms. Wang Jing serving as members. Dr. Zhou Hongbin is also a member of the Audit Committee.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLc2Ctgb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179","BK1161"],"gpt_icon":0},{"id":"2593928484","title":"Jiangsu Recbio Technology - Liu Yong Resigned as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2593928484","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593928484?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:41","pubTimestamp":1766490108,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT09B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02179"],"gpt_icon":0},{"id":"2593249287","title":"Jiangsu Recbio Appoints Xu Haoyu as Chairman After Liu Yong Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2593249287","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593249287?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:41","pubTimestamp":1766490094,"startTime":"0","endTime":"0","summary":"Jiangsu Recbio Technology Co. Ltd. has announced that Dr. Liu Yong has resigned as Chairman of the Board and Chairman of the Nomination Committee. Dr. Liu Yong will continue to serve as an executive director and General Manager. Mr. Xu Haoyu has been appointed as the new Chairman of the Board. Ms. Wang Jing has also joined as an executive director, and the Nomination Committee now includes directors of different genders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Recbio Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL6v969y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02179"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0664},{"period":"1month","weight":-0.1194},{"period":"3month","weight":-0.1993},{"period":"6month","weight":-0.4186},{"period":"1year","weight":-0.4725},{"period":"ytd","weight":0.125}],"compareEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":-0.043},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0619},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Jiangsu Recbio Technology Co Ltd is a China-based company engaged in vaccine research and development. The Company is still in the research and development stage. The Company's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009257},{"month":2,"riseRate":0.25,"avgChangeRate":-0.058747},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.06484},{"month":4,"riseRate":0.25,"avgChangeRate":-0.083572},{"month":5,"riseRate":0.25,"avgChangeRate":-0.027385},{"month":6,"riseRate":0.25,"avgChangeRate":-0.013774},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016314},{"month":8,"riseRate":0.25,"avgChangeRate":-0.033938},{"month":9,"riseRate":0.25,"avgChangeRate":-0.012227},{"month":10,"riseRate":0.5,"avgChangeRate":0.027812},{"month":11,"riseRate":0,"avgChangeRate":-0.140794},{"month":12,"riseRate":0.75,"avgChangeRate":0.059254}],"exchange":"SEHK","name":"RECBIO-B","nameEN":"RECBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RECBIO-B(02179),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RECBIO-B(02179) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RECBIO-B,02179,RECBIO-B股票,RECBIO-B股票老虎,RECBIO-B股票老虎国际,RECBIO-B行情,RECBIO-B股票行情,RECBIO-B股价,RECBIO-B股市,RECBIO-B股票价格,RECBIO-B股票交易,RECBIO-B股票购买,RECBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RECBIO-B(02179),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RECBIO-B(02179) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}